SCHEMBL24837571

SCHEMBL24837571

COC(CO)[C@H](O)C(O)=Cn1cc(F)c2c(N)ncnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.35
SRC P12931 11/20 0.34
PRMT5 O14744 3/20 0.34
WDR77 Q9BQA1 3/20 0.34
ABL1 P00519 7/20 0.33
ABL2 P42684 3/20 0.33
KDR P35968 6/20 0.32
HCK P08631 4/20 0.32
PIK3CB P42338 4/20 0.32
MTOR P42345 4/20 0.32
PIK3CG P48736 4/20 0.32
EPHB4 P54760 4/20 0.32
PRKDC P78527 4/20 0.32
PI4KB Q9UBF8 3/20 0.32
PIK3CD O00329 3/20 0.32
PIK3CA P42336 3/20 0.32
TEK Q02763 1/20 0.31
DYRK3 O43781 1/20 0.31
ROCK2 O75116 1/20 0.31
PRKD3 O94806 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24837548 1.00 EGFR (0.35) EGFRSRCPRMT5WDR77ABL1
SCHEMBL19049955 0.73 RET (0.38) SRCPRMT5WDR77KDRTEK
SCHEMBL29324056 0.72 KDR (0.39) EGFRSRCPRMT5WDR77ABL1
SCHEMBL24837761 0.72 PRMT5 (0.37) EGFRSRCPRMT5WDR77ABL1
SCHEMBL19402563 0.70 AHCY (0.39) EGFRSRCPRMT5WDR77ABL1
SCHEMBL13067511 0.68 SRC (0.42) EGFRSRCPRMT5WDR77ABL1
SCHEMBL19187882 0.67 KDR (0.40) EGFRSRCABL1ABL2KDR
SCHEMBL20058786 0.65 PIK3CB (0.43) EGFRSRCPRMT5WDR77ABL1
SCHEMBL19519734 0.63 DYRK3 (0.46) EGFRSRCABL1KDRHCK
SCHEMBL22038311 0.62 ADK (0.43) EGFRSRCPRMT5ABL1ABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216414-A1 Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus UNIV EMORY (US) 2024-07-04 US disclosed
US-20230000893-A1 Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus UNIV EMORY (US) 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000893-A1 Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus SAMHD1, PNP, NUDT1 EGFR 4525/4885SRC 2741/4885PRMT5 1461/4885
US-20240216414-A1 Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus SAMHD1, PNP, NUDT1 EGFR 4525/4885SRC 2741/4885PRMT5 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.